• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Olaparib plus bevacizumab for ovarian cancer maintenance therapy

byNiki WintersandDeepti Shroff Karhade
January 7, 2020
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy.

2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer, a majority of patients experience a relapse after 10 to 18 months, even after treatment with surgery and chemotherapy. Current maintenance therapy includes the option of bevacizumab alone. Upcoming trials are exploring PARP (polyadenosine diphosphate-ribose polymerase) inhibitors which target tumors with homologous-recombination deficiency (HRD), present in about 50% of high-grade serous ovarian tumors. This randomized phase 3 trial of olaparib, a PARP inhibitor, explored the effects of olaparib plus bevacizumab on progression-free survival. Participants with newly diagnosed, advanced, high-grade ovarian cancer were assigned in a 2:1 ratio to either receive olaparib at a dose of 300mg twice daily) or placebo between 3 to 9 weeks after the last chemotherapy.. Olaparib plus bevacizumab had an overall median progression-free survival of 22.1 months, as compared to 16.6 months with placebo plus bevacizumab. Disease progression and death rates were lower for those with BRCA-positive and HRD-positive tumors. Olaparib plus bevacizumab offered increased survival and decrease in relapse, especially in those with BRCA-positive and HRD-positive tumors. Future research should focus on determining long-term effects of this drug combination.

Click to read the study in NEJM

Relevant Reading: Olaparib in the treatment of ovarian cancer

In-Depth [randomized controlled trial]: This randomized phase 3 trial was conducted in 11 countries from 2015 to 2017, with data collected up to March 2019. 806 participants aged 18 years and older with newly diagnosed, advanced, high-grade ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer with response to platinum-taxane chemotherapy plus bevacizumab treatment were included in this study. Patients were followed to determine disease progression with imaging or until death. Overall progression-free survival was 22.1 months in the olaparib group versus 16.6 months in the placebo group (hazard ratio for disease progression or death, 0.59; 95% CI, 0.49 to 0.72; P<0.001). Patients with BRCA-positive tumors had a median progression-free survival of 37.2 months in the olaparib group and 21.7 months in the placebo group (hazard ratio for disease progression or death, 0.31; 95% CI, 0.20 to 0.47). Those with BRCA-negative tumors had a median progression-free survival of about 17 months. Patients with HRD-positive tumors had a median progression-free survival of 37.2 months in the olaparib group and 17.7 months in the placebo group (hazard ratio for disease progression or death, 0.33; 95% CI, 0.25 to 0.45). Those with HRD-negative tumors had a median progression-free survival of 16 months. The most common adverse effects in the intervention group was nausea, fatigue, anemia, and lymphopenia.

RELATED REPORTS

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Ovarian cancer screening does not reduce mortality [Classics Series]

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bevacizumab (Avastin)brcahomologous-recombination deficiency (HRD)Olaparibovarian cancerPARP (polyadenosine diphosphate-ribose polymerase) inhibitors
Previous Post

2 Minute Medicine Rewind January 6, 2020

Next Post

#VisualAbstract: Obeticholic acid for the treatment of non-alcoholic steatohepatitis

RelatedReports

Oncology

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

January 16, 2023
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

September 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Ovarian cancer screening does not reduce mortality [Classics Series]

August 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

August 10, 2022
Next Post
#VisualAbstract: Obeticholic acid for the treatment of non-alcoholic steatohepatitis

#VisualAbstract: Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

Niraparib increases progression-free survival in patients with ovarian cancer

Quick Take: Assessment of application-driven postoperative care in the pediatric tonsillectomy population: a survey-based pilot study

Adenotonsillectomy for obstructive sleep apnea in young children has no effect on cognition

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options